BPH is an enlarged prostate. The prostate goes through two main growth cycles during a man’s life. The first occurs early in puberty, when the prostate doubles in size. The second phase of growth starts around age 25 and goes on for most of the rest of a man's life. BPH most often occurs during this second growth phase.
This report aims to provide a comprehensive presentation of the global market for Oral Drugs for Benign Prostatic Hyperplasia study by Market Intellix gives insights concerning the market elements influencing the market, Market scope, Market division, and overlays shadow upon the leading market players featuring the positive cutthroat scene and patterns beating the years.
Global Oral Drugs for Benign Prostatic Hyperplasia Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Oral Drugs for Benign Prostatic Hyperplasia Market Sales, 2017-2022, 2023-2028, (K Units)
Global top five Oral Drugs for Benign Prostatic Hyperplasia companies in 2021 (%)
The global Oral Drugs for Benign Prostatic Hyperplasia market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period 2022-2028.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Alpha Blockers Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Oral Drugs for Benign Prostatic Hyperplasia include Eli Lilly, GlaxoSmithKline, Astellas Pharma, Sanofi, Pfizer, Abbott, Allergan, TEVA and Viatris, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
The study provides the Oral Drugs for Benign Prostatic Hyperplasia manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Segmental Outline:
Global Oral Drugs for Benign Prostatic Hyperplasia Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Oral Drugs for Benign Prostatic Hyperplasia Market Segment Percentages, by Type, 2021 (%)
Alpha Blockers
5-alpha Reductase Inhibitors
Others
Global Oral Drugs for Benign Prostatic Hyperplasia Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Oral Drugs for Benign Prostatic Hyperplasia Market Segment Percentages, by Application, 2021 (%)
Hospitals
Drugstores
Others
Global Oral Drugs for Benign Prostatic Hyperplasia Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Oral Drugs for Benign Prostatic Hyperplasia Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Oral Drugs for Benign Prostatic Hyperplasia revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Oral Drugs for Benign Prostatic Hyperplasia revenues share in global market, 2021 (%)
Key companies Oral Drugs for Benign Prostatic Hyperplasia sales in global market, 2017-2022 (Estimated), (K Units)
Key companies Oral Drugs for Benign Prostatic Hyperplasia sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Eli Lilly
GlaxoSmithKline
Astellas Pharma
Sanofi
Pfizer
Abbott
Allergan
TEVA
Viatris
Novartis
Merck
This Report Addresses:
– Market Intelligence enables effective decision-making
– Market estimates and forecasts from 2022 to 2028
– Growth opportunities and trend analysis
– Segment and regional revenue forecast for market evaluation
– Competitive strategy and analysis of market segments
– List of product innovations to stay on top.
– The impact of COVID-19 and how to survive in these fast-growing markets.
1 Introduction to Research & Analysis Reports
1.1 Oral Drugs for Benign Prostatic Hyperplasia Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Oral Drugs for Benign Prostatic Hyperplasia Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Oral Drugs for Benign Prostatic Hyperplasia Overall Market Size
2.1 Global Oral Drugs for Benign Prostatic Hyperplasia Market Size: 2021 VS 2028
2.2 Global Oral Drugs for Benign Prostatic Hyperplasia Revenue, Prospects & Forecasts: 2017-2028
2.3 Global Oral Drugs for Benign Prostatic Hyperplasia Sales: 2017-2028
3 Company Landscape
3.1 Top Oral Drugs for Benign Prostatic Hyperplasia Players in Global Market
3.2 Top Global Oral Drugs for Benign Prostatic Hyperplasia Companies Ranked by Revenue
3.3 Global Oral Drugs for Benign Prostatic Hyperplasia Revenue by Companies
3.4 Global Oral Drugs for Benign Prostatic Hyperplasia Sales by Companies
3.5 Global Oral Drugs for Benign Prostatic Hyperplasia Price by Manufacturer (2017-2022)
3.6 Top 3 and Top 5 Oral Drugs for Benign Prostatic Hyperplasia Companies in Global Market, by Revenue in 2021
3.7 Global Manufacturers Oral Drugs for Benign Prostatic Hyperplasia Product Type
3.8 Tier 1, Tier 2 and Tier 3 Oral Drugs for Benign Prostatic Hyperplasia Players in Global Market
3.8.1 List of Global Tier 1 Oral Drugs for Benign Prostatic Hyperplasia Companies
3.8.2 List of Global Tier 2 and Tier 3 Oral Drugs for Benign Prostatic Hyperplasia Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type - Global Oral Drugs for Benign Prostatic Hyperplasia Market Size Markets, 2021 & 2028
4.1.2 Alpha Blockers
4.1.3 5-alpha Reductase Inhibitors
4.1.4 Others
4.2 By Type - Global Oral Drugs for Benign Prostatic Hyperplasia Revenue & Forecasts
4.2.1 By Type - Global Oral Drugs for Benign Prostatic Hyperplasia Revenue, 2017-2022
4.2.2 By Type - Global Oral Drugs for Benign Prostatic Hyperplasia Revenue, 2023-2028
4.2.3 By Type - Global Oral Drugs for Benign Prostatic Hyperplasia Revenue Market Share, 2017-2028
4.3 By Type - Global Oral Drugs for Benign Prostatic Hyperplasia Sales & Forecasts
4.3.1 By Type - Global Oral Drugs for Benign Prostatic Hyperplasia Sales, 2017-2022
4.3.2 By Type - Global Oral Drugs for Benign Prostatic Hyperplasia Sales, 2023-2028
4.3.3 By Type - Global Oral Drugs for Benign Prostatic Hyperplasia Sales Market Share, 2017-2028
4.4 By Type - Global Oral Drugs for Benign Prostatic Hyperplasia Price (Manufacturers Selling Prices), 2017-2028
5 Sights By Application
5.1 Overview
5.1.1 By Application - Global Oral Drugs for Benign Prostatic Hyperplasia Market Size, 2021 & 2028
5.1.2 Hospitals
5.1.3 Drugstores
5.1.4 Others
5.2 By Application - Global Oral Drugs for Benign Prostatic Hyperplasia Revenue & Forecasts
5.2.1 By Application - Global Oral Drugs for Benign Prostatic Hyperplasia Revenue, 2017-2022
5.2.2 By Application - Global Oral Drugs for Benign Prostatic Hyperplasia Revenue, 2023-2028
5.2.3 By Application - Global Oral Drugs for Benign Prostatic Hyperplasia Revenue Market Share, 2017-2028
5.3 By Application - Global Oral Drugs for Benign Prostatic Hyperplasia Sales & Forecasts
5.3.1 By Application - Global Oral Drugs for Benign Prostatic Hyperplasia Sales, 2017-2022
5.3.2 By Application - Global Oral Drugs for Benign Prostatic Hyperplasia Sales, 2023-2028
5.3.3 By Application - Global Oral Drugs for Benign Prostatic Hyperplasia Sales Market Share, 2017-2028
5.4 By Application - Global Oral Drugs for Benign Prostatic Hyperplasia Price (Manufacturers Selling Prices), 2017-2028
6 Sights by Region
6.1 By Region - Global Oral Drugs for Benign Prostatic Hyperplasia Market Size, 2021 & 2028
6.2 By Region - Global Oral Drugs for Benign Prostatic Hyperplasia Revenue & Forecasts
6.2.1 By Region - Global Oral Drugs for Benign Prostatic Hyperplasia Revenue, 2017-2022
6.2.2 By Region - Global Oral Drugs for Benign Prostatic Hyperplasia Revenue, 2023-2028
6.2.3 By Region - Global Oral Drugs for Benign Prostatic Hyperplasia Revenue Market Share, 2017-2028
6.3 By Region - Global Oral Drugs for Benign Prostatic Hyperplasia Sales & Forecasts
6.3.1 By Region - Global Oral Drugs for Benign Prostatic Hyperplasia Sales, 2017-2022
6.3.2 By Region - Global Oral Drugs for Benign Prostatic Hyperplasia Sales, 2023-2028
6.3.3 By Region - Global Oral Drugs for Benign Prostatic Hyperplasia Sales Market Share, 2017-2028
6.4 North America
6.4.1 By Country - North America Oral Drugs for Benign Prostatic Hyperplasia Revenue, 2017-2028
6.4.2 By Country - North America Oral Drugs for Benign Prostatic Hyperplasia Sales, 2017-2028
6.4.3 US Oral Drugs for Benign Prostatic Hyperplasia Market Size, 2017-2028
6.4.4 Canada Oral Drugs for Benign Prostatic Hyperplasia Market Size, 2017-2028
6.4.5 Mexico Oral Drugs for Benign Prostatic Hyperplasia Market Size, 2017-2028
6.5 Europe
6.5.1 By Country - Europe Oral Drugs for Benign Prostatic Hyperplasia Revenue, 2017-2028
6.5.2 By Country - Europe Oral Drugs for Benign Prostatic Hyperplasia Sales, 2017-2028
6.5.3 Germany Oral Drugs for Benign Prostatic Hyperplasia Market Size, 2017-2028
6.5.4 France Oral Drugs for Benign Prostatic Hyperplasia Market Size, 2017-2028
6.5.5 U.K. Oral Drugs for Benign Prostatic Hyperplasia Market Size, 2017-2028
6.5.6 Italy Oral Drugs for Benign Prostatic Hyperplasia Market Size, 2017-2028
6.5.7 Russia Oral Drugs for Benign Prostatic Hyperplasia Market Size, 2017-2028
6.5.8 Nordic Countries Oral Drugs for Benign Prostatic Hyperplasia Market Size, 2017-2028
6.5.9 Benelux Oral Drugs for Benign Prostatic Hyperplasia Market Size, 2017-2028
6.6 Asia
6.6.1 By Region - Asia Oral Drugs for Benign Prostatic Hyperplasia Revenue, 2017-2028
6.6.2 By Region - Asia Oral Drugs for Benign Prostatic Hyperplasia Sales, 2017-2028
6.6.3 China Oral Drugs for Benign Prostatic Hyperplasia Market Size, 2017-2028
6.6.4 Japan Oral Drugs for Benign Prostatic Hyperplasia Market Size, 2017-2028
6.6.5 South Korea Oral Drugs for Benign Prostatic Hyperplasia Market Size, 2017-2028
6.6.6 Southeast Asia Oral Drugs for Benign Prostatic Hyperplasia Market Size, 2017-2028
6.6.7 India Oral Drugs for Benign Prostatic Hyperplasia Market Size, 2017-2028
6.7 South America
6.7.1 By Country - South America Oral Drugs for Benign Prostatic Hyperplasia Revenue, 2017-2028
6.7.2 By Country - South America Oral Drugs for Benign Prostatic Hyperplasia Sales, 2017-2028
6.7.3 Brazil Oral Drugs for Benign Prostatic Hyperplasia Market Size, 2017-2028
6.7.4 Argentina Oral Drugs for Benign Prostatic Hyperplasia Market Size, 2017-2028
6.8 Middle East & Africa
6.8.1 By Country - Middle East & Africa Oral Drugs for Benign Prostatic Hyperplasia Revenue, 2017-2028
6.8.2 By Country - Middle East & Africa Oral Drugs for Benign Prostatic Hyperplasia Sales, 2017-2028
6.8.3 Turkey Oral Drugs for Benign Prostatic Hyperplasia Market Size, 2017-2028
6.8.4 Israel Oral Drugs for Benign Prostatic Hyperplasia Market Size, 2017-2028
6.8.5 Saudi Arabia Oral Drugs for Benign Prostatic Hyperplasia Market Size, 2017-2028
6.8.6 UAE Oral Drugs for Benign Prostatic Hyperplasia Market Size, 2017-2028
7 Manufacturers & Brands Profiles
7.1 Eli Lilly
7.1.1 Eli Lilly Corporate Summary
7.1.2 Eli Lilly Business Overview
7.1.3 Eli Lilly Oral Drugs for Benign Prostatic Hyperplasia Major Product Offerings
7.1.4 Eli Lilly Oral Drugs for Benign Prostatic Hyperplasia Sales and Revenue in Global (2017-2022)
7.1.5 Eli Lilly Key News
7.2 GlaxoSmithKline
7.2.1 GlaxoSmithKline Corporate Summary
7.2.2 GlaxoSmithKline Business Overview
7.2.3 GlaxoSmithKline Oral Drugs for Benign Prostatic Hyperplasia Major Product Offerings
7.2.4 GlaxoSmithKline Oral Drugs for Benign Prostatic Hyperplasia Sales and Revenue in Global (2017-2022)
7.2.5 GlaxoSmithKline Key News
7.3 Astellas Pharma
7.3.1 Astellas Pharma Corporate Summary
7.3.2 Astellas Pharma Business Overview
7.3.3 Astellas Pharma Oral Drugs for Benign Prostatic Hyperplasia Major Product Offerings
7.3.4 Astellas Pharma Oral Drugs for Benign Prostatic Hyperplasia Sales and Revenue in Global (2017-2022)
7.3.5 Astellas Pharma Key News
7.4 Sanofi
7.4.1 Sanofi Corporate Summary
7.4.2 Sanofi Business Overview
7.4.3 Sanofi Oral Drugs for Benign Prostatic Hyperplasia Major Product Offerings
7.4.4 Sanofi Oral Drugs for Benign Prostatic Hyperplasia Sales and Revenue in Global (2017-2022)
7.4.5 Sanofi Key News
7.5 Pfizer
7.5.1 Pfizer Corporate Summary
7.5.2 Pfizer Business Overview
7.5.3 Pfizer Oral Drugs for Benign Prostatic Hyperplasia Major Product Offerings
7.5.4 Pfizer Oral Drugs for Benign Prostatic Hyperplasia Sales and Revenue in Global (2017-2022)
7.5.5 Pfizer Key News
7.6 Abbott
7.6.1 Abbott Corporate Summary
7.6.2 Abbott Business Overview
7.6.3 Abbott Oral Drugs for Benign Prostatic Hyperplasia Major Product Offerings
7.6.4 Abbott Oral Drugs for Benign Prostatic Hyperplasia Sales and Revenue in Global (2017-2022)
7.6.5 Abbott Key News
7.7 Allergan
7.7.1 Allergan Corporate Summary
7.7.2 Allergan Business Overview
7.7.3 Allergan Oral Drugs for Benign Prostatic Hyperplasia Major Product Offerings
7.7.4 Allergan Oral Drugs for Benign Prostatic Hyperplasia Sales and Revenue in Global (2017-2022)
7.7.5 Allergan Key News
7.8 TEVA
7.8.1 TEVA Corporate Summary
7.8.2 TEVA Business Overview
7.8.3 TEVA Oral Drugs for Benign Prostatic Hyperplasia Major Product Offerings
7.8.4 TEVA Oral Drugs for Benign Prostatic Hyperplasia Sales and Revenue in Global (2017-2022)
7.8.5 TEVA Key News
7.9 Viatris
7.9.1 Viatris Corporate Summary
7.9.2 Viatris Business Overview
7.9.3 Viatris Oral Drugs for Benign Prostatic Hyperplasia Major Product Offerings
7.9.4 Viatris Oral Drugs for Benign Prostatic Hyperplasia Sales and Revenue in Global (2017-2022)
7.9.5 Viatris Key News
7.10 Novartis
7.10.1 Novartis Corporate Summary
7.10.2 Novartis Business Overview
7.10.3 Novartis Oral Drugs for Benign Prostatic Hyperplasia Major Product Offerings
7.10.4 Novartis Oral Drugs for Benign Prostatic Hyperplasia Sales and Revenue in Global (2017-2022)
7.10.5 Novartis Key News
7.11 Merck
7.11.1 Merck Corporate Summary
7.11.2 Merck Oral Drugs for Benign Prostatic Hyperplasia Business Overview
7.11.3 Merck Oral Drugs for Benign Prostatic Hyperplasia Major Product Offerings
7.11.4 Merck Oral Drugs for Benign Prostatic Hyperplasia Sales and Revenue in Global (2017-2022)
7.11.5 Merck Key News
8 Global Oral Drugs for Benign Prostatic Hyperplasia Production Capacity, Analysis
8.1 Global Oral Drugs for Benign Prostatic Hyperplasia Production Capacity, 2017-2028
8.2 Oral Drugs for Benign Prostatic Hyperplasia Production Capacity of Key Manufacturers in Global Market
8.3 Global Oral Drugs for Benign Prostatic Hyperplasia Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Oral Drugs for Benign Prostatic Hyperplasia Supply Chain Analysis
10.1 Oral Drugs for Benign Prostatic Hyperplasia Industry Value Chain
10.2 Oral Drugs for Benign Prostatic Hyperplasia Upstream Market
10.3 Oral Drugs for Benign Prostatic Hyperplasia Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Oral Drugs for Benign Prostatic Hyperplasia Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer
Methodology/Research Approach
This research study involved the extensive usage of both primary and secondary data sources. The research process involved the study of various factors affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry, and market risks, opportunities, market barriers and challenges. The following illustrative figure shows the market research methodology applied in this report.Research Programs/Design
Historical Data (2015-2019) |
|
|
Influencing Factors |
|
|
Market Forecast (2021-2026) |
|
|
Market Size Estimation
Top-down and bottom-up approaches are used to validate the global Voluntary Carbon Offset market size market and estimate the market size for Company, regions segments, product segments and Application (end users).
The market estimations in this report are based on the marketed sale price of Voluntary Carbon Offset (excluding any discounts provided by the player, distributor, wholesaler or traders). The percentage splits, market share, and breakdowns of the product segments are derived on the basis of weights assigned to each of the segments on the basis of their utilization rate and average sale price. The regional splits of the overall Voluntary Carbon Offset market and its sub-segments are based on the percentage adoption or utilization of the given product in the respective region or country.
Major Company in the market is identified through secondary research and their market revenues determined through primary and secondary research. Secondary research included the research of the annual and financial reports of the top Company; whereas, primary research included extensive interviews of key opinion leaders and industry experts such as experienced front-line staff, directors, CEOs and marketing executives. The percentage splits, market share, Growth Rate and breakdowns of the product markets are determined through using secondary sources and verified through the primary sources.
All possible factors that influence the markets included in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data. The market size for top-level markets and sub-segments is normalized, and the effect of inflation, economic downturns, and regulatory & policy changes or other factors are not accounted for in the market forecast. This data is combined and added with detailed inputs and analysis from Market Intellix and presented in this report
The following figure shows an illustrative representation of the overall market size estimation process used for this study.
Market Breakdown and Data Triangulation
After complete market engineering with calculations for market statistics; market size estimations; market forecasting; market breakdown; and data triangulation, extensive primary research was conducted to gather information and verify and validate the critical numbers arrived at. In the complete market engineering process, both top-down and bottom-up approaches were extensively used, along with several data triangulation methods, to perform market estimation and market forecasting for the overall market segments and sub-segments listed in this report. Extensive qualitative and further quantitative analysis is also done from all the numbers arrived at in the complete market engineering process to list key information throughout the report.
Data Source
Secondary Sources
Secondary sources include such as press releases, annual reports, non-profit organizations, industry associations, governmental agencies and customs data, etc. This research study involves the usage of widespread secondary sources, directories, databases such as Bloomberg Business, Wind Info, Hoovers, Factiva (Dow Jones & Company), and TRADING ECONOMICS, and News Network, statista, Federal Reserve Economic Data, annual reports, BIS Statistics, ICIS; company house documents; CAS(American Chemical Society); investor presentations; and SEC filings of companies. Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and Hospitals study of the Voluntary Carbon Offset market. It was also used to obtain important information about the top companies, market classification and segmentation according to industry trends to the bottom-most level, and key developments related to market and technology perspectives.
Market Size |
|
|
Market Position of Top Company |
|
|
Qualitative Analysis |
|
|
Primary Sources
In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include product Company (and their competitors), opinion leaders, industry experts, research institutions, distributors, dealer and traders, as well as the raw materials suppliers and producers, etc.
The primary sources from the demand side include industry experts such as business leaders, marketing and sales directors, technology and innovation directors, supply chain executive, end use (product buyers), and related key executives from various key companies and organizations operating in the global market.
Primary research was conducted to identify segmentation Type, product price range, product Application, key Company, raw materials supply and the downstream demand, industry status and outlook, and key market dynamics such as risks, influence factors, opportunities, market barriers, industry trends, and key player strategies.
Key Executives Interviewed
Key Data Information from Primary Sources
Primary Sources | Parameters | Key Data |
Market Segments(by Application, by Type) |
|
|
Total Market |
|
|